Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules
Go back to Pulse Biosciences Completes Enrollment in the PRECISE-BTN Clinical Study Evaluating the nPulse™ Vybrance™ Percutaneous Electrode System for Symptomatic Benign Thyroid Nodules| (NASDAQ: PLSE) | Delayed: 53.87 +3.26 (6.44%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $50.61 | 52 Week High | $6.77 | |||
| Open | $50.61 | 52 Week Low | $4.03 | |||
| Day High | $54.29 | P/E | N/A | |||
| Day Low | $50.25 | EPS | $0.00 | |||
| Volume | 867,515 | |||||
